Letter | Published:

Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice

Naturevolume 434pages782786 (2005) | Download Citation


  • A Corrigendum to this article was published on 26 May 2005


Atherosclerosis is a chronic inflammatory disease, and is the primary cause of heart disease and stroke in Western countries1. Derivatives of cannabinoids such as delta-9-tetrahydrocannabinol (THC) modulate immune functions2 and therefore have potential for the treatment of inflammatory diseases. We investigated the effects of THC in a murine model of established atherosclerosis. Oral administration of THC (1 mg kg-1 per day) resulted in significant inhibition of disease progression. This effective dose is lower than the dose usually associated with psychotropic effects of THC. Furthermore, we detected the CB2 receptor (the main cannabinoid receptor expressed on immune cells2,3) in both human and mouse atherosclerotic plaques. Lymphoid cells isolated from THC-treated mice showed diminished proliferation capacity and decreased interferon-γ secretion. Macrophage chemotaxis, which is a crucial step for the development of atherosclerosis1, was also inhibited in vitro by THC. All these effects were completely blocked by a specific CB2 receptor antagonist4. Our data demonstrate that oral treatment with a low dose of THC inhibits atherosclerosis progression in the apolipoprotein E knockout mouse model, through pleiotropic immunomodulatory effects on lymphoid and myeloid cells. Thus, THC or cannabinoids with activity at the CB2 receptor may be valuable targets for treating atherosclerosis.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Libby, P. Inflammation in atherosclerosis. Nature 420, 868–874 (2002)

  2. 2

    Klein, T. W. et al. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74, 486–496 (2003)

  3. 3

    Buckley, N. E. et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396, 141–149 (2000)

  4. 4

    Rinaldi-Carmona, M. et al. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284, 644–650 (1998)

  5. 5

    Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135–1143 (2002)

  6. 6

    Mach, F. Statins as immunomodulatory agents. Circulation 109 (suppl.), II15–II17 (2004)

  7. 7

    Srivastava, M. D., Srivastava, B. I. & Brouhard, B. Δ9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40, 179–185 (1998)

  8. 8

    Zhu, L. X. et al. Δ-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J. Immunol. 165, 373–380 (2000)

  9. 9

    Yuan, M. et al. Δ9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol. 133, 124–131 (2002)

  10. 10

    Lyman, W. D., Sonett, J. R., Brosnan, C. F., Elkin, R. & Bornstein, M. B. Δ9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. 23, 73–81 (1989)

  11. 11

    Malfait, A. M. et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl Acad. Sci. USA 97, 9561–9566 (2000)

  12. 12

    Sulcova, E., Mechoulam, R. & Fride, E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59, 347–352 (1998)

  13. 13

    Brenneisen, R., Egli, A., Elsohly, M. A., Henn, V. & Spiess, Y. The effect of orally and rectally administered Δ9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int. J. Clin. Pharmacol. Ther. 34, 446–452 (1996)

  14. 14

    Chesher, G. B., Bird, K. D., Jackson, D. M., Perrignon, A. & Starmer, G. A. The effects of orally administered Δ9-tetrahydrocannabinol in man on mood and performance measures: a dose-response study. Pharmacol. Biochem. Behav. 35, 861–864 (1990)

  15. 15

    Lichtman, A. H., Poklis, J. L., Poklis, A., Wilson, D. M. & Martin, B. R. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend. 63, 107–116 (2001)

  16. 16

    Varvel, S. A., Hamm, R. J., Martin, B. R. & Lichtman, A. H. Differential effects of Δ9-THC on spatial reference and working memory in mice. Psychopharmacology (Berl.) 157, 142–150 (2001)

  17. 17

    Nakashima, Y., Plump, A. S., Raines, E. W., Breslow, J. L. & Ross, R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. 14, 133–140 (1994)

  18. 18

    Reddick, R. L., Zhang, S. H. & Maeda, N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler. Thromb. 14, 141–147 (1994)

  19. 19

    Tangirala, R. K., Rubin, E. M. & Palinski, W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36, 2320–2328 (1995)

  20. 20

    Johnson, Z. et al. Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Immunol. 173, 5776–5785 (2004)

  21. 21

    Daugherty, A. & Rateri, D. L. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circ. Res. 90, 1039–1040 (2002)

  22. 22

    Moeller, F. & Nielsen, L. B. Aortic recruitment of blood lymphocytes is most pronounced in early stages of lesion formation in apolipoprotein-E-deficient mice. Atherosclerosis 168, 49–56 (2003)

  23. 23

    Song, L., Leung, C. & Schindler, C. Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108, 251–259 (2001)

  24. 24

    Benagiano, M. et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl Acad. Sci. USA 100, 6658–6663 (2003)

  25. 25

    Laurat, E. et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 104, 197–202 (2001)

  26. 26

    Mulhaupt, F. et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res. 59, 755–766 (2003)

  27. 27

    Kwak, B. R. et al. Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation 107, 1033–1039 (2003)

  28. 28

    Giroud, C. et al. Δ9-THC, 11-OH-Δ9-THC and Δ9-THCCOOH plasma or serum to whole blood concentrations distribution ratios in blood samples taken from living and dead people. Forensic Sci. Int. 123, 159–164 (2001)

  29. 29

    Hickey, M. J., Bullard, D. C., Issekutz, A. & James, W. G. Leukocyte-endothelial cell interactions are enhanced in dermal postcapillary venules of MRL/fas(lpr) (lupus-prone) mice: roles of P- and E-selectin. J. Immunol. 168, 4728–4736 (2002)

  30. 30

    Veillard, N. R., Steffens, S., Burger, F., Pelli, G. & Mach, F. Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler. Thromb. Vasc. Biol. 24, 2339–2344 (2004)

Download references


This work was supported by grants from the Swiss National Science Foundation to F.M. and J.-L.F., from the Ernst and Lucie Schmidheiny Foundation (Geneva) to F.M., and from the Foundation for Medical Research (France) to C.A. The authors of this manuscript belong to the European Vascular Genomics Network (http://www.evgn.org), a Network of Excellence supported by the European Community's sixth Framework Programme for Research, Priority 1. We would like to thank M. Kosco-Vilbois for helpful discussion in preparing the manuscript, and M.-L. Bochaton-Piallat (Pathology Department) for technical advice.

Author information

Author notes

  1. Niels R. Veillard and Claire Arnaud: These authors contributed equally to this work


  1. Division of Cardiology, Department of Medicine, Foundation for Medical Research, University Hospital, Faculty of Medicine, 1211, Geneva, Switzerland

    • Sabine Steffens
    • , Niels R. Veillard
    • , Claire Arnaud
    • , Graziano Pelli
    • , Fabienne Burger
    •  & François Mach
  2. Division of Gastroenterology, University Hospital, Faculty of Medicine, 1211, Geneva, Switzerland

    • Jean-Louis Frossard
  3. Institute of Legal Medicine, University Hospital, Faculty of Medicine, 1211, Geneva, Switzerland

    • Christian Staub
  4. Laboratory for Molecular Neurobiology, Department of Psychiatry, University of Bonn, 53105, Bonn, Germany

    • Andreas Zimmer


  1. Search for Sabine Steffens in:

  2. Search for Niels R. Veillard in:

  3. Search for Claire Arnaud in:

  4. Search for Graziano Pelli in:

  5. Search for Fabienne Burger in:

  6. Search for Christian Staub in:

  7. Search for Andreas Zimmer in:

  8. Search for Jean-Louis Frossard in:

  9. Search for François Mach in:

Competing interests

The authors declare that they have no competing financial interests.

Corresponding author

Correspondence to François Mach.

About this article

Publication history



Issue Date



Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.